High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1416-1423

  Lopes Virella, Maria F ^a   Carter, Rickey E ^b   Baker, Nathaniel L ^c   Lachin, John ^d   Virella, Gabriel ^c  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b Mayo Clinic   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

albuminuria; diabetic nephropathy; immune complexes; modified lipoproteins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN;

ADULT; ALBUMINURIA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; URINARY EXCRETION;

ADOLESCENT; ADULT; ALBUMINURIA; ANTIGEN-ANTIBODY COMPLEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84859336649     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr454     Document Type: Article

References (47)

1. Locatelli F, Canaud B, Eckardt KU et al. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003; 18: 1716-1725 (Pubitemid 37098540)
2. Diabetes Control and Complications Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 977-986
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39: S1-S266
4. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673-689 (Pubitemid 17012586)
5. Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982; 2: 611
6. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421-426 (Pubitemid 32681484)
7. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88: 1001-1036, xi (Pubitemid 39090348)
8. Lopes-Virella MF, Carter RE, Gilbert GE et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008; 31: 2006-2012
9. Araki S, Haneda M, Koya D et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 2007; 50: 867-873 (Pubitemid 46355823)
10. Schram MT, Chaturvedi N, Schalkwijk C et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003; 26: 2165-2173 (Pubitemid 41184269)
11. Schram MT, Chaturvedi N, Schalkwijk CG et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370-378 (Pubitemid 40543311)
12. Dalla Vestra M, Mussap M, Gallina P et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005;16: S78-S82 (Pubitemid 41725090)
13. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152 (Pubitemid 351519698)
14. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007; 27: 130-143 (Pubitemid 46550311)
15. Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605 (Pubitemid 44199649)
16. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454
17. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137 (Pubitemid 36350658)
18. Bucala R, Makita Z, Vega G et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-9445 (Pubitemid 24297930)
19. HorieK, Miyata T, MaedaKet al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004 (Pubitemid 28022836)
20. Nakamura Y, Horii Y, Nishino T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-1656 (Pubitemid 24058268)
21. Virella G, Thorpe SR, Alderson NL et al. Autoimmune response to advanced glycosylation end-products of human Low Density Lipoprotein. J. Lipid Res 2003; 443: 487-493 (Pubitemid 37279696)
22. Virella G, Koskinen S, Krings G et al. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 2000; 95: 135-144 (Pubitemid 30317823)
23. Virella G. Biosynthesis[VI12], metabolism and biological properties of immunoglobulins In: Medical Immunology,Virella G (ed). Medical Immunology. 6th edn, New York, NY: Informa, 2007, pp. 65-72
24. Atchley DH, Lopes-Virella MF, Zheng D et al. Oxidized LDL-Anti-Oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 2002; 45: 1562-1571 (Pubitemid 35352050)
25. Yishak AA, Costacou T, Virella G et al. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant 2006; 21: 93-100 (Pubitemid 43064805)
26. Virella G, Derrick MB, Pate V et al. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol 2005; 12: 68-75
27. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99-111
28. The Diabetes Care and Complications Trial (DCCT) Research Group. Feasiblity of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987; 33: 2267-2271
29. Mironova M, Virella G, Virella-Lowell I et al. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol 1997; 85: 73-82 (Pubitemid 27432005)
30. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996; 16: 222-229 (Pubitemid 26056240)
31. Lopes-Virella MF, McHenry MB, Lipsitz S et al. Immune. complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007; 190: 359-369 (Pubitemid 46074026)
32. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987; 33: 2267-2271
33. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530-545
34. Agresti A. Categorical Data Analysis. 2nd edn. New York, NY: John Wiley & Sons, 2002 35.
35. Prentice RL, Pyke R. Logistic disease incidence models and casecontrol studies. Biometrika 1979; 66: 403-411 (Pubitemid 10218387)
36. Lachin J. Biostatistical Methods. The Assessment of Relative Risks. New York, NY: John Wiley and Sons, 2000 37.
37. Seliger SL. Inflammation and dyslipidemia in nephropathy: an epidemiologic perspective. Kidney Int 2006; 69: 206-208 (Pubitemid 43323067)
38. Ambrus JL Jr, Sridhar NR. Immunologic aspects of renal disease. J Am Med Assoc 1997; 278: 1938-1945 (Pubitemid 28007268)
39. Mann R, Neilson EG. Pathogenesis and treatment of immunemediated renal disease. Med Clin North Am 1985; 69: 715-750 (Pubitemid 16191082)
40. Virella G, Wohltmann H, Sagel J et al. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia 1981; 21: 184-191 (Pubitemid 11049310)
41. Nicoloff G, Blazhev A, Petrova C et al. Circulating immune complexes among diabetic children. Clin Dev Immunol 2004; 11: 61-66 (Pubitemid 38478566)
42. McCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-2478 (Pubitemid 23182498)
43. Diamond JR. Analogous pathobiological mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 39(suppl):S29-S34
44. Wheeler DC, Chana RS, Topley N et al. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994; 45: 1628-1636 (Pubitemid 24207498)
45. Fioretto P, Steffes MW, Sutherland DE et al. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. Kidney Int 1995; 48: 1929-1935
46. French JW, Yamanaka BS, Oswald R. Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol Lab Med 1967; 83: 204-210
47. Gin H, Rigalleau V, Aparicio M. Lipids, protein intake, and diabetic nephropathy. Diabetes Metab 2000; 26:45-53 (Pubitemid 30618356)